Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690813 | 0.87 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL13504162 | 0.87 | LMNA (0.58) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL29397232 | 0.86 | MEN1 (0.44) | POLBLMNAMAPK14MEN1KMT2A | |
| SCHEMBL2557164 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL13504214 | 0.86 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL4330329 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL2562402 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL2559158 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL13504268 | 0.83 | POLB (0.53) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL13504178 | 0.81 | RAB9A (0.53) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| EP-2556065-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | SMN1; SMN2 3419/4885NPC1 1221/4885RAB9A 1341/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | SMN1; SMN2 4182/4885NPC1 3313/4885RAB9A 1137/4885 |
| US-20160130256-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | SMN1; SMN2 3419/4885NPC1 1221/4885RAB9A 1341/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | SMN1; SMN2 4102/4885NPC1 3390/4885RAB9A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.